focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.50
Bid: 43.00
Ask: 46.00
Change: -1.00 (-2.20%)
Spread: 3.00 (6.977%)
Open: 45.50
High: 45.50
Low: 44.00
Prev. Close: 45.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cambridge Cognition revenue climbs despite swing to annual loss

Wed, 03rd May 2023 17:21

(Alliance News) - Cambridge Cognition Holdings PLC on Wednesday said it had a "transformative" 2022, as revenue climbed 25% against the previous year.

The Cambridge, England-based digital health products technology developer said revenue in 2022 rose to GBP12.6 million, up 25% from GBP10.1 million a year earlier. Services revenue grew by 16% in 2022 to GBP6.5 million, whilst Software revenue climbed 39% to GBP5.0 million.

However, the company swung to a pretax loss of GBP600,000 from a pretax profit of GBP300,000 year-on-year. It also swung to a loss per share of 1.3 pence, from an earnings per share of 1.4 pence.

The financial results for the year were tempered by a slightly slower-than-expected final quarter, as the company experienced delays and scope reduction associated with large orders, Cambridge Cognition explained. It added that market forecasts suggest that this is not representative of a long-term trend.

The company ended 2022 with a contracted order book of GBP17.6 million, which increased further to GBP19.1 million in January, following the acquisition of Winterlight Labs.

Cambridge Cognition bought Winterlight Labs for GBP7.0 million back in January.

Looking ahead, Cambridge Cognition said that its strong contracted order book provides "excellent" revenue visibility through 2023.

"2022 was a transformational year for Cambridge Cognition, marked by significant multi-year orders, sustained revenue growth, and the expansion of our core product set," said Chief Executive Officer Matthew Stork.

"Looking ahead, we remain committed to our objectives of driving revenue and profit growth by increasing our market share through offering the most innovative technology, supported by outstanding scientific evidence and a very experienced team, in the high-value market for CNS drug development."

Shares in Cambridge Cognition closed down 4.6% to 93.00 pence each.

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Jul 2020 16:20

Cambridge Cognition joins Covid healthcare worker investigation

(Sharecast News) - Cambridge Cognition is collaborating with 4YouandMe and the Center for International Emergency Medical Services (CIEMS), it announced on Wednesday, to investigate the use of wearables and mobile phones to measure stress recovery in front line healthcare workers caring for Covid-19 positive patients in the United States.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
30 Jun 2020 20:26

IN BRIEF: Cambridge Cognition Interim Order Intake Surges Annually

IN BRIEF: Cambridge Cognition Interim Order Intake Surges Annually

Read more
30 Jun 2020 11:00

Cambridge Cognition order intake nearly doubles in H1

(Sharecast News) - Software group Cambridge Cognition has seen its order intake almost double in the six months ended 30 June following the company's switch in focus to having a more diversified portfolio and its efforts to commercialise new products.

Read more
27 May 2020 13:10

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

Read more
27 May 2020 10:08

Cambridge Cognition inks multiple new contracts for virtual trials

(Sharecast News) - Digital brain health products developer Cambridge Cognition has secured several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1m.

Read more
5 May 2020 12:11

Cambridge Cognition 2019 Loss Widens As Revenue Falls On Sales Decline

Cambridge Cognition 2019 Loss Widens As Revenue Falls On Sales Decline

Read more
17 Mar 2020 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
17 Mar 2020 16:02

Cambridge Cognition Three Contracts Worth Total Of GBP1.4 Million

Cambridge Cognition Three Contracts Worth Total Of GBP1.4 Million

Read more
2 Mar 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
19 Feb 2020 09:40

Cambridge Cognition To Raise GBP1.4 Million; Expects Wider Annual Loss

Cambridge Cognition To Raise GBP1.4 Million; Expects Wider Annual Loss

Read more
19 Feb 2020 08:03

Cambridge Cognition losses widen amid sales slump

(Sharecast News) - Digital solutions development group Cambridge Cognition warned on Wednesday that its full-year losses were set to widen after the lower level of sales seen throughout the first half of the year extended into the third quarter

Read more
25 Nov 2019 09:36

Cambridge Cognition gains client with improved electronic assessment platform

(Sharecast News) - Brain health solutions developer Cambridge Cognition Holdings announced the launch of an improved electronic clinical outcomes assessment ('eCOA') platform on Monday, claiming it had already attracted a new client from one of the world's top 10 pharmaceutical companies.

Read more
25 Oct 2019 15:22

Cambridge Cognition hoping to ride coat-tails of Biogen Alzheimer's programme

(Sharecast News) - Cambridge Cognition announced on Friday that, Following a consultation with the US Food and Drug Administration (FDA), Biogen and Eisai have announced plans to pursue regulatory approval for 'aducanumab', which would be the first therapy to tackle clinical decline in early Alzheimer's disease.

Read more
25 Oct 2019 10:37

Cambridge Cognition Senses Opportunity In Biogen's Alzheimer Drug Push

Cambridge Cognition Senses Opportunity In Biogen's Alzheimer Drug Push

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.